Nutrition and growth in cystic fibrosis

被引:25
作者
Hankard, R [1 ]
Munck, A
Navarro, J
机构
[1] Hop Robert Debre, Clin Invest Unit, F-75019 Paris, France
[2] Hop Robert Debre, Gastroenterol & Nutr Unit, F-75019 Paris, France
关键词
cystic fibrosis; growth; nutrition; lipids;
D O I
10.1159/000064763
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Malnutrition is a common complication of chronic diseases in children and may lead to growth impairment (stunting). Malnutrition in cystic fibrosis (CF) results from increased energy expenditure, decreased energy intakes, malabsorption of ingested nutrients because of pancreatic insufficiency and chronic inflammation. Malnutrition and high levels of inflammatory cytokines affect IGF-1 production through interrelated mechanisms. Nutritional support was shown to improve both nutritional status and outcome in CF. However, some nutrients have a direct effect on the disease. n-3 fatty acids supplementation is able to correct lipid abnormalities resulting from a primary mechanism. Moreover, n-3 fatty acids have a direct effect on the inflammatory response, decreasing eicosanoid synthesis and modulating nuclear transcriptional factors nuclear factor kappaB and peroxisome proliferator-activated receptors gamma. Nutritional support may be considered part of the care of the CF patient together with antibiotics, pancreatic enzymes and physiotherapy, influencing significantly the evolution of the disease. Copyright (C) 2002 S. Karger AG, Basel.
引用
收藏
页码:16 / 20
页数:5
相关论文
共 37 条
[1]  
AUERBACH HS, 1985, LANCET, V2, P686
[2]   Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease [J].
Belluzzi, A ;
Brignola, C ;
Campieri, M ;
Pera, A ;
Boschi, S ;
Miglioli, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (24) :1557-1560
[3]   SERUM FATTY-ACID PROFILES IN CYSTIC-FIBROSIS PATIENTS AND THEIR PARENTS [J].
CHRISTOPHE, AB ;
WARWICK, WJ ;
HOLMAN, RT .
LIPIDS, 1994, 29 (08) :569-575
[4]   A COMPARISON OF SURVIVAL, GROWTH, AND PULMONARY-FUNCTION IN PATIENTS WITH CYSTIC-FIBROSIS IN BOSTON AND TORONTO [J].
COREY, M ;
MCLAUGHLIN, FJ ;
WILLIAMS, M ;
LEVISON, H .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1988, 41 (06) :583-591
[5]   Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I - A model for stunted growth in children with chronic inflammation [J].
DeBenedetti, F ;
Alonzi, T ;
Moretta, A ;
Lazzaro, D ;
Costa, P ;
Poli, V ;
Martini, A ;
Ciliberto, G ;
Fattori, E .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (04) :643-650
[6]   Nutritional benefits of neonatal screening for cystic fibrosis [J].
Farrell, PM ;
Kosorok, MR ;
Laxova, A ;
Shen, GH ;
Koscik, RE ;
Bruns, WT ;
Splaingard, M ;
Mischler, EH .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (14) :963-969
[7]   A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr-/- mice [J].
Freedman, SD ;
Katz, MH ;
Parker, EM ;
Laposata, M ;
Urman, MY ;
Alvarez, JG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (24) :13995-14000
[8]   Growth hormone decreases protein catabolism in children with cystic fibrosis [J].
Hardin, DS ;
Ellis, KJ ;
Dyson, M ;
Rice, J ;
McConnell, R ;
Seilheimer, DK .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (09) :4424-4428
[9]   Effects of growth hormone treatment in children with cystic fibrosis: The National Cooperative Growth Study experience [J].
Hardin, DS ;
Sy, JP .
JOURNAL OF PEDIATRICS, 1997, 131 (01) :S65-S69
[10]  
Huseman CA, 1996, PEDIATR PULM, V22, P90, DOI 10.1002/(SICI)1099-0496(199608)22:2<90::AID-PPUL2>3.3.CO